Compare IONQ Inc (IONQ) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IONQ Inc vs Novartis AG — how do they compare? IONQ Inc trades at $39.89 (market cap $15.98B), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 16.8× IONQ Inc's market cap, and Novartis AG pays a 3.31% dividend while IONQ Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold IONQ Inc for 33 Days and Novartis AG for 82 Days on average.
| IONQ | NVS | |
|---|---|---|
Market Cap | $15.98B | $268.57B |
Volume | 22,848,240 | 1,532,573 |
Sector | Technology | Health |
52-Week High | $82.09 | $168.62 |
52-Week Low | $26.59 | $121.80 |
Typical Hold Time | 33 Days | 82 Days |
Enterprise Value | $13.92B | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IONQ trades at $39.45, down 4.57% today, showing bearish technical signals with mixed fundamental performance. The company reported strong revenue growth ($130M in 2025, projected $246M in 2026) but significant losses (-$510M net income in 2025). Recent earnings show a pattern of beats and misses, with Q2 2026 missing expectations. Technical indicators show bearish momentum despite some oversold conditions, with key support at $36 and resistance at $41.
Outlook remains speculative with high growth potential but substantial execution risks. Analyst consensus is split with a $62.75 price target suggesting 59% upside, though profitability challenges and cash burn (-$283M operating cash flow in 2025) present significant hurdles. The quantum computing market opportunity is substantial, but IONQ must demonstrate path to profitability to justify current valuations.
NVS trades at $143.11, down 0.12% on the day, with a bearish technical signal and mixed earnings history including a recent Q1 2026 miss. The company maintains strong profitability with a 22.5% net income margin and 30.55% ROE, while recent news highlights a major $7.8B licensing deal with China's Abogen and ongoing investor scrutiny following clinical trial setbacks.
The outlook is cautious; analyst consensus is a Hold with a $146 price target, but risks include pipeline disappointments and M&A execution. Upside hinges on successful drug launches and deal integration, while downside stems from competitive pressures and regulatory challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
